Commentary Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/cancerimmunol.3.044
Exosomes, PD-L1 and aGvHD: Perspectives for WJMSCmediated Therapy
Meizhang Li1, Haitham Abdelhakim2, Mitchell W. Braun1, Andrew K. Godwin1,3,4,*
- 1Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA
- 2Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160,USA
- 3Department of Microbiology, Molecular Genetics and Immunology, Kansas City, KS 66160, USA
- 4The University of Kansas Cancer Center, Kansas City, KS 66160, USA
Corresponding Author
Andrew K. Godwin, agodwin@kumc.edu
Received Date: March 08, 2021
Accepted Date: March 29, 2021
Citation:
Li M, Abdelhakim H, Braun MW, Godwin AK. Exosomes, PD-L1 and aGvHD: Perspectives for WJMSC-mediated Therapy. J Cancer Immunol. 2021; 3(1): 98-103.
Copyright: © 2021 Li M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.